Genmab

New Capabilities

Danish drugmaker pushing three drugs through late-stage trials

Genmab's experimental head and neck cancer drug, petosemtamab, cut the risk of death in half when added to Merck's Keytruda in a late-stage trial. Shares hit a record on October 28, the company's third late-stage win in quick succession. Analysts at William Blair called the data 'exceedingly positive.'

Updated Nov 1

New Capabilities

Competitor with rinatabart sesutecan

Sofetabart mipitecan (Sofe-M) plus bevacizumab shrank tumors in 23 of 29 evaluable platinum-sensitive ovarian cancer patients, a 79.3% confirmed response rate. Every patient in the Phase 1 cohort had a response or stable disease, and the rate held in patients who had already taken a PARP inhibitor.

Updated Oct 26

New Capabilities

Co-developer of epcoritamab

AbbVie and Genmab reported on October 5 that adding epcoritamab to the R-CHOP chemotherapy combination cut the risk of disease progression or death by 51% in newly diagnosed diffuse large B-cell lymphoma. It is the first phase 3 trial of a bispecific antibody, a drug that steers the body's T cells onto cancer cells, to beat the 20-year-old R-CHOP backbone.

Updated Oct 24